2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Net sales of major and new products<br />
Net sales <strong>2010</strong>: € 2 786 million<br />
Core products<br />
Mature products<br />
In € million<br />
Cimzia®<br />
Vim pat®<br />
Neupro®<br />
Keppra® 1<br />
Zyrtec®<br />
venlafaxine XR<br />
Xyzal® 2<br />
Tussionex<br />
Nootropil®<br />
omeprazole<br />
Metadate<br />
Other products<br />
+163%<br />
+190%<br />
+34% 82<br />
+3%<br />
-15%<br />
+49%<br />
-13%<br />
-46%<br />
-5%<br />
+1%<br />
66<br />
65<br />
-26% 54<br />
-9%<br />
80<br />
133<br />
115<br />
162<br />
198<br />
229<br />
Core products combined sales of € 413 million<br />
up by 127% in the first <strong>full</strong> <strong>year</strong> of sales – on<br />
track to meet peak sales guidance<br />
660<br />
942<br />
Total mature products sales reached € 2 373 million<br />
down by 5% following further generic competition<br />
Note: % constant exchange rates<br />
1 Including € 83 million of Keppra ® XR in the U.S.<br />
31<br />
2 Excluding Xyzal ® U.S. revenue to <strong>UCB</strong> of € 28 million from profit-sharing with sanofi-aventis
Change language